CMPS
COMPASS Pathways Plc
$5.54
$0.00(0.00%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$712.95M
Volume
1.37M
52W Range
$2.25 - $8.90
Target Price
$21.83
Company Overview
| Mkt Cap | $712.95M | Price | $5.54 |
| Volume | 1.37M | Change | +0.00% |
| P/E Ratio | -4.6 | Open | $5.69 |
| Revenue | -- | Prev Close | $5.54 |
| Net Income | $-155.1M | 52W Range | $2.25 - $8.90 |
| Div Yield | N/A | Target | $21.83 |
| Overall | 18 | Value | -- |
| Quality | -- | Technical | 18 |
No chart data available
About COMPASS Pathways Plc
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Sector: Industrials
Industry: Research and Development in Biotechnology
Latest News
LifeSci Capital Keeps Their Buy Rating on COMPASS Pathways (CMPS)
TipRanks Auto-Generated Intelligence Newsdesk•11 days ago
LifeSci Capital Keeps Their Buy Rating on COMPASS Pathways (CMPS)
TipRanks Auto-Generated Intelligence Newsdesk•11 days ago
RBC Capital Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)
TipRanks Auto-Generated Intelligence Newsdesk•14 days ago
Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
TipRanks Auto-Generated Intelligence Newsdesk•14 days ago
Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
TipRanks Auto-Generated Intelligence Newsdesk•14 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CMPS | $5.54 | 0% | 1.37M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |